These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24080590)

  • 1. Genetic association with response to intravitreal ranibizumab for neovascular age-related macular degeneration in the Han Chinese population.
    Yuan D; Yuan D; Liu X; Yuan S; Xie P; Liu Q
    Ophthalmologica; 2013; 230(4):227-32. PubMed ID: 24080590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration.
    McKibbin M; Ali M; Bansal S; Baxter PD; West K; Williams G; Cassidy F; Inglehearn CF
    Br J Ophthalmol; 2012 Feb; 96(2):208-12. PubMed ID: 21558292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.
    Abedi F; Wickremasinghe S; Richardson AJ; Islam AF; Guymer RH; Baird PN
    Ophthalmology; 2013 Aug; 120(8):1641-8. PubMed ID: 23582991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration.
    Smailhodzic D; Muether PS; Chen J; Kwestro A; Zhang AY; Omar A; Van de Ven JP; Keunen JE; Kirchhof B; Hoyng CB; Klevering BJ; Koenekoop RK; Fauser S; den Hollander AI
    Ophthalmology; 2012 Nov; 119(11):2304-11. PubMed ID: 22840423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients.
    Park UC; Shin JY; McCarthy LC; Kim SJ; Park JH; Chung H; Yu HG
    Mol Vis; 2014; 20():1680-94. PubMed ID: 25558172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD.
    Cruz-Gonzalez F; Cabrillo-Estévez L; López-Valverde G; Cieza-Borrella C; Hernández-Galilea E; González-Sarmiento R
    Graefes Arch Clin Exp Ophthalmol; 2014 Mar; 252(3):469-75. PubMed ID: 24522370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT).
    Hagstrom SA; Ying GS; Pauer GJT; Sturgill-Short GM; Huang J; Callanan DG; Kim IK; Klein ML; Maguire MG; Martin DF;
    Ophthalmology; 2013 Mar; 120(3):593-599. PubMed ID: 23337555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics of response to anti-VEGF therapy in exudative age-related macular degeneration.
    Dedania VS; Grob S; Zhang K; Bakri SJ
    Retina; 2015 Mar; 35(3):381-91. PubMed ID: 25635578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic factors associated with response to intravitreal ranibizumab in Korean patients with neovascular age-related macular degeneration.
    Park UC; Shin JY; Kim SJ; Shin ES; Lee JE; McCarthy LC; Newcombe PJ; Xu CF; Chung H; Yu HG
    Retina; 2014 Feb; 34(2):288-97. PubMed ID: 23842101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment.
    Yamashiro K; Tomita K; Tsujikawa A; Nakata I; Akagi-Kurashige Y; Miyake M; Ooto S; Tamura H; Yoshimura N
    Am J Ophthalmol; 2012 Jul; 154(1):125-36. PubMed ID: 22465368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population.
    Tian J; Qin X; Fang K; Chen Q; Hou J; Li J; Yu W; Chen D; Hu Y; Li X
    Pharmacogenomics; 2012 May; 13(7):779-87. PubMed ID: 22594510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population.
    Chang W; Noh DH; Sagong M; Kim IT
    Mol Vis; 2013; 19():702-9. PubMed ID: 23559864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Single-Nucleotide Polymorphisms in Age-Related Macular Degeneration With Pseudodrusen: Secondary Analysis of Data From the Comparison of AMD Treatments Trials.
    Lin LY; Zhou Q; Hagstrom S; Maguire MG; Daniel E; Grunwald JE; Martin DF; Ying GS;
    JAMA Ophthalmol; 2018 Jun; 136(6):682-688. PubMed ID: 29801032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetics in neovascular age-related macular degeneration susceptibility and treatment response to anti-VEGF intravitreal injection: A case series study.
    Chang FY; Huang CH; Yang CH; Chang JT; Yang CM; Ho TC; Hsieh YT; Lai TT; Lin CW; Lin CP; Chen YC; Lai YJ; Chen PL; Hsu JS; Chen TC
    Clin Exp Ophthalmol; 2024 Aug; 52(6):655-664. PubMed ID: 38757252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age-related macular degeneration.
    Cobos E; Recalde S; Anter J; Hernandez-Sanchez M; Barreales C; Olavarrieta L; Valverde A; Suarez-Figueroa M; Cruz F; Abraldes M; Pérez-Pérez J; Fernández-Robredo P; Arias L; García-Layana A
    Acta Ophthalmol; 2018 Mar; 96(2):e201-e212. PubMed ID: 28926193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration.
    Hermann MM; van Asten F; Muether PS; Smailhodzic D; Lichtner P; Hoyng CB; Kirchhof B; Grefkes C; den Hollander AI; Fauser S
    Ophthalmology; 2014 Apr; 121(4):905-10. PubMed ID: 24365177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials.
    Maguire MG; Daniel E; Shah AR; Grunwald JE; Hagstrom SA; Avery RL; Huang J; Martin RW; Roth DB; Castellarin AA; Bakri SJ; Fine SL; Martin DF;
    Ophthalmology; 2013 Oct; 120(10):2035-41. PubMed ID: 23706946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement factor H and high-temperature requirement A-1 genotypes and treatment response of age-related macular degeneration.
    Tsuchihashi T; Mori K; Horie-Inoue K; Gehlbach PL; Kabasawa S; Takita H; Ueyama K; Okazaki Y; Inoue S; Awata T; Katayama S; Yoneya S
    Ophthalmology; 2011 Jan; 118(1):93-100. PubMed ID: 20678803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of Response to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment of Age-Related Macular Degeneration.
    Shah AR; Williams S; Baumal CR; Rosner B; Duker JS; Seddon JM
    Am J Ophthalmol; 2016 Mar; 163():154-166.e8. PubMed ID: 26705092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration.
    Orlin A; Hadley D; Chang W; Ho AC; Brown G; Kaiser RS; Regillo CD; Godshalk AN; Lier A; Kaderli B; Stambolian D
    Retina; 2012 Jan; 32(1):4-9. PubMed ID: 21878851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.